January 2021

Wu et al. demonstrate that mutations in the B1.1.7 did not affect the neutralisation capacity of mRNA-1273-vaccine induced antibodies, however mutations in the B.1.351 variant drastically reduced the neutralisation capacity…

Interim analysis indicates that vaccine candidate Ad26.COV2.S is safe and immunogenic in both younger and older adults. This finding, in combination with the results in preclinical challenge studies, has supported…

The two doses of mRNA-1273 vaccine showed 94.1% efficacy at preventing COVID-19 illness including severe disease in persons 18 or older. Aside from transient local and systemic reactions, no safety…